In patients who acquire resistance to BCMA-targeting bispecific antibodies, what is the most commonly identified mechanism of resistance according to the data presented?
Loss of CD8 effector T-cells from the tumor microenvironment
Mutations in BCMA leading to biallelic deletion or monoallelic loss plus altered extracellular domain binding, occurring in >80% of cases monoallelic loss plus alteration in the external domain of BCMA
Downregulation of STING pathway in myeloma cells